- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00835861
Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes (MIPOD)
Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)
Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin. Metformin is widely used in the non-pregnant population for glycemic control, and has been used in pregnancy for other indications without adverse maternal or fetal outcomes. What remains unproven is the ability of Metformin to adequately control glucose in women during pregnancy.
Our goal is to randomize 100 women who enter pregnancy with diabetes that is controlled by either diet or an oral agent and women who are found to have an abnormal glucose challenge test at less than 20 weeks to either standard treatment with weight based Regular and neutral protamine Hagedorn (NPH) insulin or Metformin. Our hypothesis is that Metformin will provide glycemic control that is equivalent to insulin in these women.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- University of North Carolina Hospitals Obstetric Clinics
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Receiving prenatal care at University of North Carolina (UNC), Chapel Hill Obstetric clinics and planning delivery at UNC Women's Hospital
- Diagnosis of Diabetes prior to pregnancy with use of an oral hypoglycemic agent or dietary control
- Diagnosis of early gestational diabetes prior to 20 weeks gestation via abnormal 3 hour glucose challenge testing using the national diabetes data group (NDDG)criteria
- Less than 24 weeks at study enrollment
- Singleton or twin pregnancy
- English or Spanish speaking
- Able to give informed consent
Exclusion Criteria:
- End organ complications of diabetes (retinopathy, renal insufficiency, etc.)
- Prior need for insulin for glycemic control
- History of diabetic ketoacidosis (DKA) or hyperosmolar state
- Prior adverse reaction (ie. lactic acidosis) or allergy to Metformin
- Kidney or liver disease
- Significant medical co-morbidities (lupus, cystic fibrosis, etc.) Hypertension controlled on one medication, well controlled asthma, and well controlled thyroid disease are not excluded.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Metformin
Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation.
After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
|
Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education.
They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy.
At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control.
If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
다른 이름들:
|
활성 비교기: Insulin
Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation.
After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
|
Women randomized to the Insulin group will receive standard diet and glycemic monitoring education.
They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner.
At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Blood Glucose Measurements
기간: Daily fasting and 1-hr post prandial measures were taken from time of enrollment until delivery
|
Patients self monitored glucose measures throughout pregnancy to aid glycemic control.
Fasting morning measures and postprandial measures were taken at 1 hour after breakfast, lunch, and dinner.
|
Daily fasting and 1-hr post prandial measures were taken from time of enrollment until delivery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of Patients With Obstetric Complications
기간: Throughout pregnancy until hospital discharge following delivery.
|
Maternal complications were stillbirths, major malformations, shoulder dystocia, or postpartum hemorrhage requiring transfusion.
|
Throughout pregnancy until hospital discharge following delivery.
|
Maternal Weight Gain
기간: Baseline throughout pregnancy until last prenatal visit.
|
Baseline throughout pregnancy until last prenatal visit.
|
|
Number of Babies With Neonatal Hypoglycemia
기간: Time of delivery through hospital discharge
|
Initial neonatal glucose < 40 mg/dL
|
Time of delivery through hospital discharge
|
Glycosylated Hemoglobin (HbA1c) by Pregnancy Trimester
기간: 1st, 2nd, and 3rd trimester
|
1st, 2nd, and 3rd trimester
|
|
Percent of Glucose Values at or Below Fasting Goal (<95 mg/dL)
기간: Baseline throughout pregnancy until time of delivery
|
NUMBER OF ASSESSMENTS OF FASTING GLUCOSE VALUES <95
|
Baseline throughout pregnancy until time of delivery
|
Percent of Glucose Values at or Below Postprandial Goal (<130 mg/dL)
기간: Baseline throughout pregnancy until time of delivery
|
NUMBER OF ASSESSMENTS OF POSTPRANDIAL GLUCOSE VALUES <130
|
Baseline throughout pregnancy until time of delivery
|
Number of Episodes Maternal Hypoglycemia
기간: Baseline throughout pregnancy until time of delivery
|
Maternal glucose < 60 mg/dL
|
Baseline throughout pregnancy until time of delivery
|
Number of Babies With Adverse Neonatal Outcomes
기간: Delivery until hospital discharge
|
Resuscitation in the delivery room, preterm birth < 37 weeks, neonatal intensive care unit care, birth injury or diagnosis of neonatal complication, glucose infusion, antibiotics, or phototherapy.
|
Delivery until hospital discharge
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ashley Hickman, MD, University of North Carolina, Chapel Hill
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- UNC08-0898
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
임신에 대한 임상 시험
-
The Nazareth Hospital, Israel완전한Streptococcus B Carrier State Complicating Pregnancy이스라엘
Metformin에 대한 임상 시험
-
Tan Tock Seng Hospital모병
-
Poznan University of Medical SciencesUniversity of California, San Diego알려지지 않은
-
University Hospital, AntwerpHasselt University; University Hospital, Ghent; AZ Sint-Jan AV; National MS Center Melsbroek; Noorderhart Pelt모병
-
Bing He모집하지 않고 적극적으로
-
Torrent Pharmaceuticals Limited완전한